These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
72. Circulating PCSK9 levels are positively correlated with NMR-assessed atherogenic dyslipidaemia in patients with high cardiovascular risk. Guardiola M; Plana N; Ibarretxe D; Cabré A; González M; Ribalta J; Masana L Clin Sci (Lond); 2015 Jun; 128(12):877-82. PubMed ID: 25649668 [TBL] [Abstract][Full Text] [Related]
73. Cell-associated heparin-like molecules modulate the ability of LDL to regulate PCSK9 uptake. Galvan AM; Chorba JS J Lipid Res; 2019 Jan; 60(1):71-84. PubMed ID: 30463987 [TBL] [Abstract][Full Text] [Related]
74. The biological relevance of PCSK9: when less is better…. Mbikay M; Chrétien M Biochem Cell Biol; 2022 Jun; 100(3):189-198. PubMed ID: 35263196 [TBL] [Abstract][Full Text] [Related]
75. Association between proprotein convertase subtilisin/kexin 9 (PCSK9) and lipoprotein subclasses in children with type 1 diabetes mellitus: Effects of glycemic control. Bojanin D; Vekic J; Milenkovic T; Vukovic R; Zeljkovic A; Stefanovic A; Janac J; Ivanisevic J; Mitrovic K; Miljkovic M; Spasojevic-Kalimanovska V Atherosclerosis; 2019 Jan; 280():14-20. PubMed ID: 30453116 [TBL] [Abstract][Full Text] [Related]
76. Roles of the low density lipoprotein receptor and related receptors in inhibition of lipoprotein(a) internalization by proprotein convertase subtilisin/kexin type 9. Romagnuolo R; Scipione CA; Marcovina SM; Gemin M; Seidah NG; Boffa MB; Koschinsky ML PLoS One; 2017; 12(7):e0180869. PubMed ID: 28750079 [TBL] [Abstract][Full Text] [Related]
77. Response to letter regarding article, "Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and -independent mechanisms". Rashid S; Tavori H; Brown PE; Linton MF; He J; Giunzioni I; Fazio S Circulation; 2015 May; 131(18):e428. PubMed ID: 25940973 [No Abstract] [Full Text] [Related]
78. The Proprotein Convertases in Hypercholesterolemia and Cardiovascular Diseases: Emphasis on Proprotein Convertase Subtilisin/Kexin 9. Seidah NG; Abifadel M; Prost S; Boileau C; Prat A Pharmacol Rev; 2017 Jan; 69(1):33-52. PubMed ID: 27920219 [TBL] [Abstract][Full Text] [Related]
79. PCSK9 Association With Lipoprotein(a). Tavori H; Christian D; Minnier J; Plubell D; Shapiro MD; Yeang C; Giunzioni I; Croyal M; Duell PB; Lambert G; Tsimikas S; Fazio S Circ Res; 2016 Jun; 119(1):29-35. PubMed ID: 27121620 [TBL] [Abstract][Full Text] [Related]
80. Removal of plasma mature and furin-cleaved proprotein convertase subtilisin/kexin 9 by low-density lipoprotein-apheresis in familial hypercholesterolemia: development and application of a new assay for PCSK9. Hori M; Ishihara M; Yuasa Y; Makino H; Yanagi K; Tamanaha T; Kishimoto I; Kujiraoka T; Hattori H; Harada-Shiba M J Clin Endocrinol Metab; 2015 Jan; 100(1):E41-9. PubMed ID: 25313916 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]